RCPA develops guidance for pharmacogenomic testing
Guidance for the cutting edge of personalised medicines.
The Royal College of Pathologists of Australasia (RCPA) has successfully completed a ground-breaking pharmacogenomics (PGx) project aimed at providing national guidance for PGx testing in Australia. Funded by Australian Genomics and conducted in partnership with the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) and the Pharmaceutical Society of Australia (PSA), the project marks a significant milestone in precision medicine and patient care.
The indications were developed by a multidisciplinary advisory group of prescribers, pathologists, scientists, pharmacists and pharmacologists with expertise in pharmacogenomics, and with feedback from Australian organisations representing healthcare professionals. They are informed by peer-reviewed International and Australian guidelines and approved product labels.
National indications for PGx testing have been developed for 35 drugs commonly used in Australia. A living document is now hosted on the RCPA website, providing clinicians and health professionals with readily accessible guidance on when to consider PGx testing for specific drugs.
A list of the drugs included in this resource can be found here. This resource indicates whether the pharmacogenomic test is Medicare rebated on the specific page for that drug.
Further information or enquiries can be directed to rcpa@rcpa.edu.au
